Purpose

Although SGLT-2i initially acquired prominence for usage in diabetes, they later emerged as the top medication class in both cardiovascular diseases and disorders. However, they still do not have the proper bioavailability (50–70%); therefore, it has different options such as using either a higher dose amount or dose frequency.

Methods

The aim of this review is focusing on current trials of SGLT-2i with less side effects and improved patient compliance, which lead to different options such as using either a higher dose amount or dose frequency.

Results

With the acceleration of clinical studies, it would not be surprising to witness the introduction of SGLT-2i nano-based systems as a commercial product in the upcoming years.

Conclusion

Research on SGLT-2i-based systems is being conducted to facilitate the development of new drug delivery methods such as microemulsion and self-nanoemulsifying drug delivery system.

Graphical Abstract

中文翻译：

---

SGLT-2i：针对低生物利用度的基于纳米颗粒的策略、解决方案和临床应用

目的

尽管 SGLT-2i 最初因治疗糖尿病而受到关注，但后来它们成为心血管疾病和紊乱的顶级药物类别。然而，它们仍然没有适当的生物利用度（50-70%）；因此，它有不同的选择，例如使用更高的剂量或剂量频率。

方法

本次综述的目的是关注目前 SGLT-2i 的试验，该试验具有较少的副作用和提高的患者依从性，这导致了不同的选择，例如使用更高的剂量或剂量频率。

结果

随着临床研究的加速，在未来几年见证 SGLT-2i 纳米系统作为商业产品的推出也就不足为奇了。

结论

正在进行基于SGLT-2i的系统的研究，以促进新的药物递送方法的开发，例如微乳和自纳米乳化药物递送系统。

图形概要